PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Mirabegron - Overactive bladder (adults)
PAD Profile : Mirabegron - Overactive bladder (adults) Important
Keywords :
OAB, urge incontinence, urinary incontinence, urinary frequency, LUTS, over-active bladder, urinary urgency
Brand Names Include :
Betmiga
Important Information :
Solifenacin is 1st line.
Mirabegron for use when antimuscarinics are contraindicated, patients with CNS adverse effects or patients requiring a more potent treatment.
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Darifenacin hydrobromide
- Flavoxate hydrochloride
- Oxybutynin
- Propiverine hydrochloride
- Solifenacin
- Fesoterodine fumarate
- Trospium chloride
- Tolterodine
- Imipramine hydrochloride
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Guidelines (National)
Committee Recommendations
Date
Committee Name
Narrative
06 March 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The APC supports patients in trialling a treatment break of their overactive bladder medicines.
A "Leaflet for trial of stopping mirabegron" can be found in the documents section.
06 September 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
Solifenacin is the 1st line treatment option.
Mirabegron is reserved for patients:
- in whom an antimuscarininc is contraindicated
- requiring (and can tolerate) a more potent treatment
- 3rd line where experiencing CNS adverse effects (confusion, drowsiness, hallucinations)
See Selection Tool for locally agreed OAB treament options
Associated BNF Codes
07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.02. Drugs for urinary frequency enuresis and incontinence